Daewoong pharmaceutical Co.,Ltd

KSE 069620.KS

Daewoong pharmaceutical Co.,Ltd Capital Expenditure for the year ending December 31, 2023: USD -91.14 M

Daewoong pharmaceutical Co.,Ltd Capital Expenditure is USD -91.14 M for the year ending December 31, 2023, a -1.82% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Daewoong pharmaceutical Co.,Ltd Capital Expenditure for the year ending December 31, 2022 was USD -89.51 M, a -42.99% change year over year.
Daewoong pharmaceutical Co.,Ltd Capital Expenditure for the year ending December 31, 2021 was USD -62.60 M, a -14.24% change year over year.
Daewoong pharmaceutical Co.,Ltd Capital Expenditure for the year ending December 31, 2020 was USD -54.80 M, a -26.88% change year over year.
Daewoong pharmaceutical Co.,Ltd Capital Expenditure for the year ending December 31, 2019 was USD -43.19 M, a 15.33% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

KSE: 069620.KS

Daewoong pharmaceutical Co.,Ltd

CEO	Mr. Chang-Jae Lee
IPO Date	Sept. 29, 2005
Location	South Korea
Headquarters	12, Bongeunsa-ro 114-gil
Employees	1,710
Sector	Health Care
Industries Pharmaceuticals

Description

Daewoong Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. The company was founded in 1945 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years